Systemic mRNA aggregates elicit immunologic reprogramming that unlocks anti-cancer immunity.

IF 3.5 4区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-08-19 DOI:10.1080/21645515.2025.2543599

Hector R Mendez-Gomez, John A Ligon, Ashley P Ghiaseddin, Elias J Sayour

引用次数: 0

Abstract

Successful cancer immunotherapy requires novel approaches that overcome intratumoral immunosuppression and peripheral tolerance. In a recent manuscript describing intravenously administered mRNA-loaded lipid particle aggregates (RNA-LPAs), we demonstrate the ability to reprogram both the tumor microenvironment and periphery enabling cancer-specific immunity simultaneously generated to compete against immunologically 'cold' malignancies like glioblastoma.

查看原文本刊更多论文

系统性mRNA聚集引发免疫重编程，解锁抗癌免疫。

成功的癌症免疫治疗需要克服肿瘤内免疫抑制和外周耐受的新方法。在最近的一篇描述静脉注射mrna负载脂质颗粒聚集体（RNA-LPAs）的论文中，我们证明了重新编程肿瘤微环境和外周的能力，使癌症特异性免疫同时产生，以对抗免疫“冷”恶性肿瘤，如胶质母细胞瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

CiteScore

7.90

自引率

8.30%

发文量

489

审稿时长

3-6 weeks

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.